# Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine

> **NCT04113772** · NA · UNKNOWN · sponsor: **Sutphin Drugs** · enrollment: 4 (estimated)

## Conditions studied

- Hereditary Tyrosinemia, Type I

## Interventions

- **DRUG:** Nitisinone
- **DRUG:** Orfadin

## Key facts

- **NCT ID:** NCT04113772
- **Lead sponsor:** Sutphin Drugs
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2019-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04113772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04113772, "Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04113772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*